Systematic review of economic evaluation studies: Are vaccination programs efficient in Spain?

Vaccine

Volumn 31, Issue 13, 2013, Pages 1656-1665

  García Altés, Anna ^a  

^a Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

Author keywords

Decision making; Economic evaluation; Public health; Vaccination programs

Indexed keywords

CHICKENPOX VACCINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

BIBLIOGRAPHIC DATABASE; CHOLERA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EPIDEMIC MENINGITIS; HEALTH CARE UTILIZATION; HUMAN; INFLUENZA VACCINATION; POLIOMYELITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; SPAIN; SYSTEMATIC REVIEW;

COMMUNICABLE DISEASES; COSTS AND COST ANALYSIS; HUMANS; SPAIN; STATISTICS AS TOPIC; VACCINATION; VACCINES;

EID: 84875256637     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.029     Document Type: Review

References (83)

1. Catalá-López F., álvarez-Martín E., Gènova-Maleras R., Morant-Ginestar C. Relación en España entre la investigación sanitaria financiada por el Sistema Nacional de Salud y la carga de enfermedad en la comunidad. Rev Esp Salud Publica 2009, 83:137-151.
2. Hinman A.R. Global progress in infectious disease control. Vaccine 1998, 16:1116-1121.
3. Ozawa S., Stack M.L., Bishai D.M., Mirelman A., Friberg I.K., Niessen L., et al. During the 'decade of vaccines', the lives of 6. 4 million children valued at $231 billion could be saved. Health Aff (Millwood) 2011, 30(6):1010-1020.
4. Stack M.L., Ozawa S., Bishai D.M., Mirelman A., Tam Y., Niessen L., et al. Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity. Health Aff (Millwood) 2011, 30(6):1021-1028.
5. Roberts J.A. The economics of infectious disease 2006, Oxford University Press, Nueva York.
6. Catalá-López F., García-Altés A., Alvarez-Martín E., Génova-Maleras R., Morant-Ginestar C. Economic evaluation of interventions for infectious diseases in Spain: systematic review and comparative analysis. Rev Esp Quimioter 2011, 24(September (3)):143-150.
7. Neumann P.J., Fang C.H., Cohen J.T. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics 2009, 27(10):861-872.
8. Valderas J.M., Mendivil J., Parada A., Losada-Yáñez M., Ferrer M., Alonso J. Construcción de un filtro geográfico para la identificación en PubMed de estudios realizados en España. Rev Esp Cardiol 2006, 59(12):1244-1251.
9. Murray C.J.L., López A. The global burden of disease 1996, Harvard University Press, Boston.
10. Catalá-López F., García-Altés A., Alvarez-Martín E., Gènova-Maleras R., Morant-Ginestar C., Parada A. Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?. BMC Health Serv Res 2011, 11:75.
11. Instituto Nacional de Estadística. Products and Services/The CPI in one click/Do you wish to update a rental income? <> [last accessed: 02.10.12]. http://www.ine.es/calcula/.
12. Plans Rubió P., Garrido Morales P., Salleras Sanmartí L. The cost-effectiveness of pneumococcal vaccination in Catalonia. Rev Esp Salud Publica 1995, 69(5):409-417.
13. Plans P. Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain). Gac Sanit 2002, 16(5):392-400.
14. Ament A., Baltussen R., Duru G., Rigaud-Bully C., de Graeve D., Ortqvist A., et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000, 31(2):444-450.
15. Evers S.M., Ament A.J., Colombo G.L., Konradsen H.B., Reinert R.R., Sauerland D., et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007, 26(8):531-540.
16. Asensi F., De Jose M., Lorente M., Moraga F., Ciuryla V., Arikian S., et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 2004, 7(1):36-51.
17. Díez Domingo J., Ridao M., Latour J., Ballester A., Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999, 17(11-12):1306-1311.
18. Navas E., Salleras L., Gisbert R., Domínguez A., Timoner E., Ibáñez D., et al. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 2005, 23(17-18):2342-2348.
19. Jiménez F.J., Guayar P., Rubio C., Villasante P., Guayar E. Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Br J Med Econ 1996, 10:193-202.
20. Lema Devesa M.C., Farjas Abadía M.P., Bouzas Caamaño E., Escudero Pereira J., Domínguez Hernández V. Infección neumocócica en el Complejo Universitario Juan Canalejo: análisis coste/beneficio de una política de inmunización al alta hospitalaria. Vacunas 2002, 3:94-98.
21. Picazo J., Méndez C., Oyagüez I., Casado M.A., Guijarro P. Coste-utilidad de la incorporación de las nuevas vacunas antineumocócicas conjugadas al programa de vacunación de la comunidad de Madrid. Impacto sobre la enfermedad neumocócica invasora. Vacunas 2010, 11(Suppl. 1):23-31.
22. Morano R., Pérez F., Brosa M., Escolano I.P. Cost-effectiveness analysis of pneumococcal vaccination in Spain. Gac Sanit 2011, 25(4):267-273.
23. López Alemany J.M., Cortés Bordoy J., Gil de Miguel A. Human papilomavirus tetravalent vacciones cost-effectiveness study. Rev Esp Econ Salud 2007, 6(7):400-408.
24. Largeron N., Rémy V., Oyee J., San-Martín M., Cortés J., Olmos L. Análisis de coste-efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España. Vacunas 2008, 9:3-11.
25. Diaz M., de Sanjose S., Ortendahl J., O'Shea M., Goldie S.J., Bosch F.X., et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010, 46(16):2973-2985.
26. Castellsagué X., San Martín M., Cortés J., González A., Remi V. Impact of the human papilloma virus (HPV) quadrivalent (types 6/11/16/18) vaccine in HPV-associated diseases in Spain. Prog Obstet Ginecol 2008, 51(9):520-530.
27. Perez-Rubio A., Luquero F.J., Bouza J.M., Castrodeza Sanz J.J., Bachiller Luque M.R., de Lejarazu R.O., et al. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain. Infez Med 2011, 19(September (3)):166-175.
28. Diez-Domingo J., Suriñach N.L., Alcalde N.M., Betegón L., Largeron N., Trichard M. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health 2010, 10:469.
29. Pérez-Rubio A., Castrodeza Sanz J.J., Gil Costa M., Luquero Alcalde F.J., Eiros Bouza J., Ortiz de Lejarazu R. Social and economic impact of chicken pox vaccine at 15 months of age. Castile and Leon, Spain, 2004. Rev Esp Salud Publica 2008, 82(1):101-109.
30. Díez-Domingo J., Ridao-López M., Gutiérrez-Gimeno M.V., Puig-Barberá J., Lluch-Rodrigo J.A., Pastor-Villalba E. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine 2011, 29(52):9640-9648.
31. Forcén T., Garuz R., Cabasés J., Ruiz de Ocenda M., Martínez J.A., Izko J. Economic evaluation of routine vaccination of 15 month old children against chicken-pox-zoster. An Sist Sanit Navar 2000, 23(1):115-124.
32. Martínez-Zárate M.P., Antoñanzas F., Pradas R. Evaluación económica de la vacunación sistemática frente al virus de la varicela-zóster. PharmacoEconomics 2005, 2(1):9-19. Spanish Research Articles.
33. Peña-Rey I., Pérez-Farinós N., Cortés-García M., Amela-Heras C. Cost-effectiveness of varicella vaccination in Spanish adolescents. Gac Sanit 2004, 18(4):287-294.
34. Lenne X., Diez Domingo J., Gil A., Ridao M., Lluch J.A., Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 2006, 24(47-48):6980-6989.
35. Gavira F.J., Lardinois R. Cost-effectiveness analysis of antigrippal vaccination in a rural population (La Victoria, Cordoba). Med Clin (Barc) 1990, 94(20):777-781.
36. Navas E., Salleras L., Domínguez A., Ibáñez D., Prat A., Sentís J., et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine 2007, 25(16):3233-3239.
37. Salleras L., Navas E., Domínguez A., Ibáñez D., Prat A., Garrido P., et al. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices. Vaccine 2009, 27(25-26):3454-3458.
38. Almuzara Sauras I. Análisis económico del coste de la gripe aplicado a la provincia de Huesca. Rev San Hig Pub 1987, 61:1012-1028.
39. Pradas R., Antoñanzas F., Zoellner Y. Evaluación económica de la vacunación antigripal por los servicios médicos de empresa. Rev Esp Econ Salud 2004, 3(4):227-233. Publica 2010;84(4):353-69.
40. de Juanes J.R., Cisterna R., Sanz J., Magaz S., Badia X. Efficiency of influenza vaccination in the working population in Spain. Gac Sanit 2006, 20(2):101-107.
41. Martín Fernández J. Analysis of a economic model of a populational influenza immunization strategy in healthy employees. Rev Esp Salud Publica 2006, 80(3):219-231.
42. Aballéa S., De Juanes J.R., Barbieri M., Martin M., Chancellor J., Oyagüez I., et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain. Vaccine 2007, 25(39-40):6900-6910.
43. Antoñanzas F., Forcén T., Garuz R. A cost-effectiveness analysis of vaccination against the hepatitis B virus. Med Clin (Barc) 1992, 99(2):41-46.
44. Garuz R., Torrea J.L., Arnal J.M., Forcen T., Trinxet C., Anton F., et al. Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine 1997, 15(15):1652-1660.
45. Guillén Grima F., Espín Ríos M.I. Cost-effectiveness analysis of different alternatives of universal vaccination against hepatitis B in the region of Murcia. Med Clin (Barc) 1995, 104(4):130-136.
46. Rivera F., Lissen E., Vázquez R., Arroyo F., Sánchez Quijano A., García D.p., et al. Cost-benefit analysis of a program for vaccination against hepatitis B in health personnel of a hospital. Med Clin (Barc) 1984, 83:611-614.
47. Jönsson B., Horisberger B., Bruguera M., Matter L. Cost-benefit analysis of hepatitis-B vaccination, A computerized decision model for Spain. Int J Technol Assess Health Care 1991, 7(3):379-402.
48. Navas E., Salleras L., Gisbert R., Dominguez A., Bruguera M., Rodríguez G., et al. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine 2005, 23(17-18):2185-2189.
49. Díez Redondo M.P., Almaraz A., Jiménez Rodríguez-Vila M., Santamaría A., de Castro J., Torrego J.C., et al. Comparison of two vaccination strategies against hepatitis A and B in patients with chronic hepatitis C. Rev Esp Enferm Dig 2009, 101(4):265-274.
50. Arnal J.M., Frisas O., Garuz R., Antoñanzas F. Cost-effectiveness of hepatitis A immunisation in Spain. Pharmacoeconomics 1997, 12(3):361-373.
51. Barricarte A., Navarro J.A., Urtiaga M. Análisis coste-efectividad de la inmunización frente al meningococo serogrupo C con vacuna conjugada. Vacunas 2001, 2(3):91-95.
52. Jiménez F.J., Guallar-Castillón P., Rubio Terrés C., Guallar E. Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain. Pharmacoeconomics 1999, 15(1):75-83.
53. López-Gigosos R., Garcia-Fortea P., Calvo M.J., Reina E., Diez-Diaz R., Plaza E. Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea. BMC Infect Dis 2009, 9(16):65.
54. Acedo L., Díez-Domingo J., Moraño J.A., Villanueva R.J. Mathematical modeling of respiratory syncytial virus (RSV): vaccination strategies and budget applications. Epidemiol Infect 2010, 138(6):853-860.
55. García-Altés A. Twenty years of health care economic analysis in Spain: are we doing well?. Health Econ 2001, 10(8):715-729.
56. Esperato A., García-Altés A. Health promotion: a profitable investment? Economic efficiency of preventive interventions in Spain. Gac Sanit 2007, 21(2):150-161.
57. Catalá-López F., García-Altés A. Economic evaluation of healthcare interventions during more than 25 years in Spain (1983-2008). Rev Esp Salud Pública 2010, 84(4):353-369.
58. Elixhauser A., Luce B.R., Taylor W.R., Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care 1993, 31:JS1-JS11.
59. Elixhauser A., Halpern M., Schmier J., Luce B.R. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 1998, 36:MS1-MS9.
60. Neumann P.J. Costing and perspective in published cost-effectiveness analysis. Med Care 2009, 47(7 (Suppl. 1)):S28-S32.
61. López Bastida J., Oliva J., Antoñanzas F., García-Altés A., Gisbert R., Mar J., et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias 2008, Plan de Calidad para el Sistema Nacional de Salud. Servicio de Evaluación del Servicio Canario de la Salud, Madrid, Informes de Evaluación de Tecnologías Sanitarias: SESCS No 2006/22.
62. López Bastida J., Oliva J., Antoñanzas F., García-Altés A., Gisbert R., Mar J., et al. A proposed guideline for economic evaluation of health technologies. Gac Sanit 2010, 24(2):154-170.
63. Puig-Junoy J., Peiró S. De la utilidad de los medicamentos al valor terapéutico añadido y a la relación coste-efectividad incremental. Rev Esp Salud Pública 2009, 83(1):59-70.
64. Porta M. The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low?. Prev Med 2009, 48:407-410.
65. Puig-Junoy J., Lopez-Valcarcel B.G. Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. Prev Med 2009, 48(May (5)):444-448.
66. Ferko N., Postma M., Gallivan S., Kruzikas D., Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 2008, 26(Suppl. 5):F3-F15.
67. Drummond M., Chevat C., Lothgren M. Do we fully understand the economic value of vaccines?. Vaccine 2007, 25(August (32)):5945-5957.
68. Bloom D.E., Canning D., Weston M. The value of vaccination. World Economics 2005, 6(3):15-39.
69. Kim J.J. The role of cost-effectiveness in U.S. vaccination policy. N Engl J Med 2011, 365(November (19)):1760-1761.
70. Ehreth J. The value of vaccination: a global perspective. Vaccine 2003, 21(October (27-30)):4105-4117.
71. Levine O.S., Bloom D.E., Cherian T., de Quadros C., Sow S., Wecker J., et al. The future of immunisation policy, implementation, and financing. Lancet 2011, 378(9789):439-448.
72. Larson H.J., Cooper L.Z., Eskola J., Katz S.L., Ratzan S. Addressing the vaccine confidence gap. Lancet 2011, 378(9790):526-535.
73. Bell C.M., Urbach D.R., Ray J.G., Bayoumi A., Rosen A.B., Greenberg D., et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006, 332:699-703.
74. Drummond M.F. Economic evaluation of pharmaceuticals: science or marketing?. Pharmacoeconomics 1998, 14(1):1-9.
75. Barbieri M., Drummond M.F. Conflict of interest in industry-sponsored economic evaluations: real or imagined?. Curr Oncol Rep 2001, 3(5):410-413.
76. Clement F.M., Harris A., Li J.J., Yong K., Lee K.M., Manns B.J. Using effectiveness and cost-effectiveness to make drug coverage decisions. A comparison of Britain, Australia, and Canada. JAMA 2009, 302(13):1437-1443.
77. Oliva J., Del Llano J., Sacristán J.A. Análisis de las evaluaciones económicas de tecnologías sanitarias realizadas en España en la década 1990-2000. Gac Sanit 2002, 16(Suppl. 2):2-11.
78. Asociación Economía de la Salud (AES). Posición de la Asociación de Economía de la Salud en relación a la necesidad de un mayor uso de la evaluación económica en las decisiones que afectan a la financiación pública de las prestaciones y tecnologías en el Sistema Nacional de Salud. <> [last accessed: 02.10.12]. http://www.aes.es/Publicaciones/AESEE.pdf.
79. BOE. Boletín Oficial del Estado. Ley 16/2003, de 28 de mayo, de Cohesión y Calidad del Sistema Nacional de Salud. BOE núm. 128, de 29/05/2003.
80. BOE. Boletín Oficial del Estado. Real Decreto 1030/2006, de 15 de septiembre, por el que se establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actualización. BOE núm. 222, de 16/10/2006.
81. Ministerio de Sanidad y Consumo Plan de Calidad para el Sistema Nacional de Salud 2007, Ministerio de Sanidad y Consumo, Madrid.
82. BOE. Boletín Oficial del Estado. Real Decreto-ley 16/2012, de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones. BOE núm. 98, de 24/4/2012.
83. Ministerio de Sanidad y Consumo Criterios para fundamentar la modificación de los programas de vacunas 2004, Ministerio de Sanidad y Consumo, Madrid, [last accessed: 02.10.2012]. http://www.msc.es/ciudadanos/proteccionSalud/vacunaciones/docs/criteriosVacunas.pdf.